127 related articles for article (PubMed ID: 27845595)
1. CNA-loaded PLGA nanoparticles improve humoral response againstS. aureus-mediated infections in a mouse model: subcutaneous vs. nasal administration strategy.
Genta I; Colonna C; Conti B; Caliceti P; Salmaso S; Speziale P; Pietrocola G; Chiesa E; Modena T; Dorati R
J Microencapsul; 2016 Dec; 33(8):750-762. PubMed ID: 27845595
[TBL] [Abstract][Full Text] [Related]
2. Sub-unit vaccine against S. aureus-mediated infections: set-up of nano-sized polymeric adjuvant.
Colonna C; Dorati R; Conti B; Caliceti P; Genta I
Int J Pharm; 2013 Aug; 452(1-2):390-401. PubMed ID: 23707885
[TBL] [Abstract][Full Text] [Related]
3. Inverse micellar sugar glass (IMSG) nanoparticles for transfollicular vaccination.
Mittal A; Schulze K; Ebensen T; Weissmann S; Hansen S; Guzmán CA; Lehr CM
J Control Release; 2015 May; 206():140-52. PubMed ID: 25795506
[TBL] [Abstract][Full Text] [Related]
4. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity.
Pawar D; Mangal S; Goswami R; Jaganathan KS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):550-9. PubMed ID: 23831265
[TBL] [Abstract][Full Text] [Related]
5. Nasal vaccination with poly(β-amino ester)-poly(d,l-lactide-co-glycolide) hybrid nanoparticles.
Sinani G; Sessevmez M; Koray Gök M; Özgümüş S; Okyar A; Oya Alpar H; Cevher E
Int J Pharm; 2017 Aug; 529(1-2):1-14. PubMed ID: 28629979
[TBL] [Abstract][Full Text] [Related]
6. Intranasal delivery of cationic PLGA nano/microparticles-loaded FMDV DNA vaccine encoding IL-6 elicited protective immunity against FMDV challenge.
Wang G; Pan L; Zhang Y; Wang Y; Zhang Z; Lü J; Zhou P; Fang Y; Jiang S
PLoS One; 2011; 6(11):e27605. PubMed ID: 22110686
[TBL] [Abstract][Full Text] [Related]
7. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
Slütter B; Bal S; Keijzer C; Mallants R; Hagenaars N; Que I; Kaijzel E; van Eden W; Augustijns P; Löwik C; Bouwstra J; Broere F; Jiskoot W
Vaccine; 2010 Aug; 28(38):6282-91. PubMed ID: 20638455
[TBL] [Abstract][Full Text] [Related]
8. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.
Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P
J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926
[TBL] [Abstract][Full Text] [Related]
9. Development of PLGA nanoparticle loaded dissolving microneedles and comparison with hollow microneedles in intradermal vaccine delivery.
Mönkäre J; Pontier M; van Kampen EEM; Du G; Leone M; Romeijn S; Nejadnik MR; O'Mahony C; Slütter B; Jiskoot W; Bouwstra JA
Eur J Pharm Biopharm; 2018 Aug; 129():111-121. PubMed ID: 29803720
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity Evaluation of Recombinant Staphylococcus aureus Enterotoxin B (rSEB) and rSEB-loaded Chitosan Nanoparticles Following Nasal Administration.
Hosseini SA; Nazarian S; Ebrahimi F; Hajizade A
Iran J Allergy Asthma Immunol; 2020 Apr; 19(2):159-171. PubMed ID: 32372629
[TBL] [Abstract][Full Text] [Related]
11. Immunization against HTLV-I with chitosan and tri-methylchitosan nanoparticles loaded with recombinant env23 and env13 antigens of envelope protein gp46.
Amirnasr M; Fallah Tafti T; Sankian M; Rezaei A; Tafaghodi M
Microb Pathog; 2016 Aug; 97():38-44. PubMed ID: 27235335
[TBL] [Abstract][Full Text] [Related]
12. Surface-functionalized, pH-responsive poly(lactic-co-glycolic acid)-based microparticles for intranasal vaccine delivery: Effect of surface modification with chitosan and mannan.
Li Z; Xiong F; He J; Dai X; Wang G
Eur J Pharm Biopharm; 2016 Dec; 109():24-34. PubMed ID: 27569030
[TBL] [Abstract][Full Text] [Related]
13. Antigen delivery via hydrophilic PEG-b-PAGE-b-PLGA nanoparticles boosts vaccination induced T cell immunity.
Rietscher R; Schröder M; Janke J; Czaplewska J; Gottschaldt M; Scherließ R; Hanefeld A; Schubert US; Schneider M; Knolle PA; Lehr CM
Eur J Pharm Biopharm; 2016 May; 102():20-31. PubMed ID: 26940132
[TBL] [Abstract][Full Text] [Related]
14. Protective effect of recombinant staphylococcal enterotoxin A entrapped in polylactic-co-glycolic acid microspheres against Staphylococcus aureus infection.
Chen L; Li S; Wang Z; Chang R; Su J; Han B
Vet Res; 2012 Mar; 43(1):20. PubMed ID: 22429499
[TBL] [Abstract][Full Text] [Related]
15. pH-Responsive Poly(D,L-lactic-co-glycolic acid) Nanoparticles with Rapid Antigen Release Behavior Promote Immune Response.
Liu Q; Chen X; Jia J; Zhang W; Yang T; Wang L; Ma G
ACS Nano; 2015 May; 9(5):4925-38. PubMed ID: 25898266
[TBL] [Abstract][Full Text] [Related]
16. PLGA (85:15) nanoparticle based delivery of rL7/L12 ribosomal protein in mice protects against Brucella abortus 544 infection: A promising alternate to traditional adjuvants.
Singh D; Somani VK; Aggarwal S; Bhatnagar R
Mol Immunol; 2015 Dec; 68(2 Pt A):272-9. PubMed ID: 26442664
[TBL] [Abstract][Full Text] [Related]
17. Targeted nasal vaccination provides antibody-independent protection against Staphylococcus aureus.
Misstear K; McNeela EA; Murphy AG; Geoghegan JA; O'Keeffe KM; Fox J; Chan K; Heuking S; Collin N; Foster TJ; McLoughlin RM; Lavelle EC
J Infect Dis; 2014 May; 209(9):1479-84. PubMed ID: 24273045
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
Bento D; Staats HF; Gonçalves T; Borges O
Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
[TBL] [Abstract][Full Text] [Related]
19. Pathogen-Mimicking Polymeric Nanoparticles based on Dopamine Polymerization as Vaccines Adjuvants Induce Robust Humoral and Cellular Immune Responses.
Liu Q; Jia J; Yang T; Fan Q; Wang L; Ma G
Small; 2016 Apr; 12(13):1744-57. PubMed ID: 26849717
[TBL] [Abstract][Full Text] [Related]
20. Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticles.
Pan L; Zhang Z; Lv J; Zhou P; Hu W; Fang Y; Chen H; Liu X; Shao J; Zhao F; Ding Y; Lin T; Chang H; Zhang J; Zhang Y; Wang Y
Int J Nanomedicine; 2014; 9():5603-18. PubMed ID: 25506214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
